Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib
{{output}}
The administration of target inhibitors is paramount to grant the longest survival in patients with ALK-positive non-small cell lung cancer (NSCLC). The eventual resistance to tyrosine kinase inhibitors (TKI) is monitored clinically and radiologically for prom... ...
